Project Grant R01AG082433
- This Project Grant award of $451,000.00 from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), will fund research to understand how aging and chronic lymphocytic leukemia (CLL) impact the metabolic function of T cells. The goal is to develop strategies to rescue T cell aging and improve the production of chimeric antigen receptor (CAR) T cells from elderly cancer patients. The award will support cutting-edge metabolism assays to evaluate the...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Sloan-Kettering Institute for Cancer Research in New York aims to understand the cellular mechanisms that regulate lymph node maintenance and atrophy during aging. The $513,957 award will support research to investigate the role of lymphatic endothelial cell NF-κB signaling in adult lymph node homeostasis. Key objectives include determining the effects of aging on lymph node lymphatic...
- The National Institute on Aging (NIA) awarded a $486,750 Project Grant under the Aging Research federal grant program (CFDA 93.866) to The Jackson Laboratory in Bar Harbor, Maine. The goal of this 2-year project is to investigate the impact of age-related clonal hematopoiesis mutations in peripheral immune cells on the etiology and progression of Alzheimer's disease using mouse models. The research aims to establish whether functional changes in peripheral immune cells influence the onset and...
- This $147,486 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research to investigate the role of chaperone-mediated autophagy (CMA) in cellular senescence and its contribution to aging. The research aims to understand: 1) if CMA activity changes upon induction of senescence, 2) if CMA modulates senescence kinetics and by what mechanism(s), 3) if CMA is required for senescent cell clearance, and 4) if restoring CMA activity...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $159,492 to Weill Medical College of Cornell University to support research focused on identifying and characterizing clonal expansions in aging and aging-related diseases. The key products/services to be delivered under this award include: Developing tools to enable the identification of candidate somatic variants at scale from publicly available data using machine learning approaches. Applying...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $408,600.00 to Trustees of Tufts College, doing business as Tufts University School of Medicine, to conduct research on the role of cytosolic DNA sensing in regulating tissue-resident macrophage function and organismal longevity. The key objectives of this research project are to: 1) Ascertain the role of endogenous retroelements in shaping tissue-resident macrophage survival and...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research provides $133,353 to Mayo Clinic to investigate the molecular mechanisms of T cell-mediated surveillance of senescent cells under both physiological and aging conditions. The research aims to define how senescent cells deploy their secretome to sensitize human T cells, assess co-stimulatory and co-inhibitory interactions between senescent cells and T cells, and perform translational studies...
- This $492,250 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research to determine if regulatory T cells (Tregs) are dysfunctional in Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital, will conduct comprehensive scientific investigations to understand the role of Tregs in AD pathology. This includes isolating and functionally assessing Tregs derived from AD patients to evaluate their potential...
- This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
INVESTIGATING THE INTERFACE OF NLRX1 AND IMMUNE AGING - PROJECT SUMMARY/ABSTRACT: ALTERATIONS IN THE IMMUNE SYSTEM OCCUR WITH AGING, LIKELY CONTRIBUTING TO INFECTIONS AND MALIGNANCIES. IN T CELLS, PROBABLY THE MOST PROMINENT CHANGE WITH AGING IS MEMORY T CELL EXPANSION. A POSSIBLE MECHANISM FOR THIS FINDING IS IMMUNE STIMULATION OVER A LIFETIME. THE NUCLEOTIDE BINDING DOMAIN AND LEUCINE-RICH-REPEAT-CONTAINING (NLR) PROTEIN X1 OR NLRX1 LOCATED IN MITOCHONDRIA IS A NEGATIVE REGULATOR OF MULTIPLE INFLAMMATORY PATHWAYS INCLUDING THE RETINOIC ACID-INDUCIBLE GENE I (RIG-I), NLR PYRIN DOMAIN CONTAINING 3 (NLRP3) INFLAMMASOME, AND NF-KB SIGNALING. OUR PUBLISHED AND PRELIMINARY STUDIES SUPPORT THE POSSIBLE IMPLICATION OF NLRX1 IN AGING. AGING INDUCED THE REDUCTION OF NLRX1 IN MURINE LUNGS. THE LUNGS FROM WHOLE BODY NLRX1 NULL MUTANT (-/-) OR KNOCKOUT (KO) MICE REVEALED INCREASED LUNG COMPLIANCE, A KEY FEATURE OF THE "AGING LUNG"8. OF INTEREST, WE FOUND DECREASED EXPRESSION OF NLRX1 IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OF OLDER ADULTS, RAISING THE IMPLICATION OF NLRX1 IN IMMUNE AGING. INDEED, THE NLRX1 KO MICE HAVE CHANGES IN T CELL IMMUNITY KNOWN TO OCCUR WITH AGING. THESE CHANGES INCLUDE AN EXPANSION OF MEMORY CD4+ AND CD8+ T CELLS, DECREASED NAIVE T CELL SURVIVAL AND IL-2 PRODUCTION, INCREASED T CELL EXHAUSTION MOLECULES AND EFFECTOR CYTOKINE IFN-G. OUR RNA-SEQ ANALYSIS ON EFFECTOR MEMORY (EM) CD4+ T CELLS OF WT AND NLRX1 KO MICE HIGHLIGHTED AN AGING-LIKE CHANGE IN THE GLOBAL GENE EXPRESSION PROFILE IN NLRX1 KO MICE, IMPLYING THE ROLE OF NLRX1 IN ALTERING T CELL IMMUNITY WITH AGING. THIS POINT IS FURTHER SUPPORTED BY NOTICING WELL-KNOWN AGE-ASSOCIATED CHANGES IN NLRX1 KO MICE, INCLUDING REDUCED MITOCHONDRIAL MASS, NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) AND SIRT1 AS WELL AS ENHANCED MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS), MTOR ACTIVATION, HYPOXIA-INDUCIBLE FACTOR 1-ALPHA (HIF-1A) EXPRESSION AND CELLULAR EXHAUSTION WHICH ARE MECHANISTICALLY LINKED. HOWEVER, OUR UNDERSTANDING REMAINS POOR ABOUT HOW NLRX1 PLAYS IN ALTERING T CELL IMMUNITY IN THE CONTEXT OF AGING BIOLOGY AND WHETHER SUCH CHANGES CAN BE RESTORED BY INCREASING NLRX1 IN AGED HOSTS. HERE WE ADDRESS THIS QUESTION BASED ON THE HYPOTHESES THAT DECREASED NLRX1 AUGMENTS T CELL AGING BY MECHANISTICALLY AFFECTING A SET OF AGING-ASSOCIATED MOLECULES (I.E., MITOCHONDRIAL ROS, NAD+, SIRT1, AND MTOR) AND THAT SUCH AGING-ASSOCIATED CHANGES CAN BE IMPROVED BY RESTORING NLRX1 EXPRESSION IN OLD MICE. THE GOAL OF OUR PROPOSAL IS TO TEST THESE HYPOTHESES WITH THE FOLLOWING SPECIFIC AIMS: 1) AIM 1. ELUCIDATE THE MECHANISM OF HOW NLRX1 DEFICIENCY ALTERS T CELL CHARACTERISTICS, ESPECIALLY ONES RELATED TO IMMUNE AGING; 2) AIM 2. ELUCIDATE THE IMPLICATION OF MITOCHONDRIAL ROS AND NAD+ IN INDUCING T CELL IMMUNITY CHANGES VIA AFFECTING MTOR ACTIVITY IN NLRX1 KO MICE; AND 3) AIM 3. ELUCIDATE WHETHER RESTORATION OF NLRX1 IN VIVO CAN ATTENUATE AGING-ASSOCIATED CHANGES IN T CELL IMMUNITY. THE RESULTS OF OUR STUDY WILL REVEAL A NOVEL MECHANISM OF T CELL AGING IN THE SETTING OF DECREASED NLRX1, PROVIDING A POTENTIAL ANTI-AGING STRATEGY BY RESTORING NLRX1.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $344.7k | 8/21/25 | ||
| Not listed | $351.8k | 8/28/24 |